Dyslipidemia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes

DelveInsight's "Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dyslipidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia Market Forecast
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Dyslipidemia Market Report:
• The Dyslipidemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2025, In the PROLONG-ANG3 trial, Eli Lilly's solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA, demonstrated reductions in apolipoprotein B among patients with mixed dyslipidemia. Similarly, in a Phase 2 study, SHR-1918, a monoclonal antibody developed by Jiangsu Hengrui Pharmaceuticals, showed decreases in LDL, triglycerides, and other lipid levels in patients with inadequately managed hyperlipidemia.
• In November 2024, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage clinical biopharmaceutical firm developing oral, non-statin medications for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), who do not respond well to existing therapies, today announced positive topline results from its Phase 3 TANDEM clinical trial (NCT06005597). The TANDEM trial will support global regulatory submissions for the 10 mg obicetrapib and 10 mg ezetimibe fixed-dose combination in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, whose LDL-C remains inadequately controlled despite receiving maximally tolerated lipid-lowering therapy.
• In August 2024, At the European Society of Cardiology (ESC) 2024 meeting, Dr. Erin Michos discussed the success of obicetrapib trials thus far. NewAmsterdam has demonstrated promising results in all Phase II trials, including ROSE2, TULIP, ROSE, and OCEAN, which assessed obicetrapib as both a monotherapy and combination therapy, showing its ability to significantly lower low-density lipoprotein (LDL) levels. The completion of patient enrollment in the Phase III TANDEM trial marks a key milestone towards the potential launch of obicetrapib, bringing NewAmsterdam closer to offering a new treatment option for dyslipidemia, heterozygous familial hypercholesterolemia (HeFH), and/or atherosclerotic cardiovascular disease (ASCVD).
• In July 2024, NewAmsterdam Pharma reported positive results from the first of its four pivotal Phase III trials, demonstrating that its lead cardiovascular candidate, obicetrapib, effectively lowers cholesterol levels. The BROOKLYN trial (NCT05425745) is the initial study in NewAmsterdam's portfolio, focused on assessing obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains inadequately managed despite receiving the maximum tolerated lipid-lowering therapy.
• The most common form of dyslipidemia observed was hypercholesterolemia (total cholesterol level ≥ 5.0 mmol/L), with an average prevalence of 58.2%, ranging from 50% to 67% based on the region.
• The standardized prevalence figures for dyslipidemia in Switzerland, characterized by either self-reported drug use alone or a combination of self-reported drug use and a self-reported diagnosis of dyslipidemia, were 3.7% (95% CI 3.3-4.1%) and 12.2% (95% CI 11.5-12.9%) for women, and 6.3% (95% CI 5.7-6.8%) and 16.9% (95% CI 16.0-17.8%) for men, respectively.
• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others
• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others
• The Dyslipidemia epidemiology based on gender analyzed that females are affected more as compared to males, in case of Dyslipidemia
• The Dyslipidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dyslipidemia pipeline products will significantly revolutionize the Dyslipidemia market dynamics.

Dyslipidemia Overview
Dyslipidemia is a medical condition characterized by abnormal levels of lipids (fats) in the blood, such as cholesterol and triglycerides. It typically involves high levels of low-density lipoprotein (LDL or "bad" cholesterol), low levels of high-density lipoprotein (HDL or "good" cholesterol), or elevated triglycerides. Dyslipidemia increases the risk of cardiovascular diseases, including heart attacks and strokes. It can result from genetics, poor diet, obesity, lack of exercise, or underlying conditions like diabetes. Treatment often includes lifestyle changes and medications such as statins to help manage lipid levels.

Get a Free sample for the Dyslipidemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyslipidemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dyslipidemia Epidemiology Segmentation:
The Dyslipidemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Dyslipidemia
• Prevalent Cases of Dyslipidemia by severity
• Gender-specific Prevalence of Dyslipidemia
• Diagnosed Cases of Episodic and Chronic Dyslipidemia

Download the report to understand which factors are driving Dyslipidemia epidemiology trends @ Dyslipidemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyslipidemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia market or expected to get launched during the study period. The analysis covers Dyslipidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dyslipidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dyslipidemia Therapies and Key Companies
• Pemafibrate (K-877): Kowa Company
• AZD8233: AstraZeneca And Parexel
• Rosuvastatin: AstraZeneca
• GW856553: GlaxoSmithKline
• A3309: Albireo
• TA-8995: Xention Ltd
• Alirocumab: Sanofi
• Muraglitazar: Bristol-Myers Squibb
• Atorvastatin (Lipilou): Chong Kun Dang Pharmaceutical
• MK1903: Merck Sharp & Dohme LLC
• Lapaquistat acetate: Takeda
• PPAR alpha: Eli Lilly and Company

Discover more about therapies set to grab major Dyslipidemia market share @ Dyslipidemia Treatment Landscape
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyslipidemia Market Drivers
• Increasing global geriatric population
• Increase in the prevalence of lifestyle related and cardiovascular disorders

Dyslipidemia Market Barriers
• Significant proportion of treated patients do not reach recommended treatment goal
• Increase in availability of generic drugs

Scope of the Dyslipidemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others, and others
• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others
• Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and Dyslipidemia emerging therapies
• Dyslipidemia Market Dynamics: Dyslipidemia market drivers and Dyslipidemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dyslipidemia Unmet Needs, KOL's views, Analyst's views, Dyslipidemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.